# Janssen

Carvykti — BCMA、与传奇合作.

Source: https://cn.bioecon.ru/companies/janssen/
Updated: 2026-07-11

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 传奇生物于2017年收到$3.5亿首付款，并在与Janssen的合作中已实现$3亿里程碑付款。 | https://www.sec.gov/Archives/edgar/data/1801198/000115752322000455/a52692636ex99_1.htm |
| 产能 | 新泽西州Raritan基地可支持每年最多10,000名患者的治疗。 | https://www.biospace.com/press-releases/legend-biotech-reports-fourth-quarter-and-full-year-2025-results-and-recent-highlights, https://www.fiercepharma.com/pharma/jj-legend-invest-150m-belgium-cell-therapy-facility-new-carvykti-rival-looms |
| 生产基地 | 生产基地包括新泽西州Raritan及比利时根特（Tech Lane与Obelisc设施）。此外还在新泽西州Morris Plains的Novartis进行合同生产。 | https://www.biospace.com/press-releases/legend-biotech-reports-fourth-quarter-and-full-year-2025-results-and-recent-highlights, https://www.fiercepharma.com/pharma/jj-legend-invest-150m-belgium-cell-therapy-facility-new-carvykti-rival-looms |
| 监管批准 | 2022年获FDA批准用于复发/难治性多发性骨髓瘤，2024年获批用于二线治疗。欧盟与日本亦已批准。 | https://www.businesswire.com/news/home/20240405663733/en/Legend-Biotech%e2%80%99s-CARVYKTI%c2%ae-ciltacabtagene-autoleucel-Becomes-the-First-and-Only-BCMA-Targeted-CAR-T-Cell-Therapy-Approved-by-the-FDA-for-Second-Line-Treatment-of-Multiple-Myeloma, https://www.fda.gov/media/156572/download, https://www.myeloma.org/treatment/carvykti-ciltacabtagene-autoleucel |
| 营收 | CARVYKTI 2025全年净贸易销售额约$19亿。传奇生物2025年总收入为$10.289亿。 | https://www.biospace.com/press-releases/legend-biotech-reports-fourth-quarter-and-full-year-2025-results-and-recent-highlights, https://www.manilatimes.net/2026/03/10/tmt-newswire/globenewswire/legend-biotech-reports-fourth-quarter-and-full-year-2025-results-and-recent-highlights/2296756 |

独立来源: biospace.com, businesswire.com, fda.gov, fiercepharma.com, manilatimes.net, myeloma.org, sec.gov

## 技术

- [CAR-T 细胞疗法](https://cn.bioecon.ru/technology/car-t-cell-therapy/)
- [双特异性与多特异性抗体](https://cn.bioecon.ru/technology/bispecific-antibodies/)